Journal: bioRxiv
Article Title: Tumor-infiltrating CD27 - IgD - regulatory B cells suppress cytotoxic CD8 + T cell responses in renal cell carcinoma
doi: 10.1101/2025.07.08.663720
Figure Lengend Snippet: (A) Density UMAPs showing the distribution of IL10 hi , TGFB hi , TXN hi , AHR hi , HAVCR2 hi , TIGIT hi , CD274 hi and PDCD1 hi RCC-resident B cells. (B) Dotplot showing the proportion of cells expressing a Breg score comprising IL10, CD274, AHR, TXN, LAG3, TIGIT, CTLA4, CD86, TGFB1, and GZMB (dot size), and their average expression levels (color intensity) in the tumor, tumor margin, BK, and blood. (C) Spatial analysis of segmented CD20 + Bregs in a representative TLS. Staining of DAPI (dark blue) overlaid with cell segmentation (gating strategy shown in Figure S5A) of CD20 + IL-10 + Bregs (red), CD20 + TGFβ + Bregs (green), and CD20 + IL-10 + TGFβ + Bregs (orange). Scale bar = 100µm. (D) Cumulative data showing the frequencies of CD20 + IL-10 + Bregs, CD20 + TGFβ + Bregs, CD20 + IL-10 + TGFβ + within ROIs; * p <0.05, ** p <0.01. 13 ROIs across n =3 biologically independent samples. One-way ANOVA with Tukey’s test for multiple comparisons. Error bars represented as mean±SEM. (E) Spatial analysis of segmented CD138 + Bregs in a representative TLS. Staining of DAPI (dark blue) overlaid with cell segmentation (gating strategy shown in Figure S5A) of CD138 + IL-10 + Bregs (pink), CD138 + TGFβ + Bregs (dark green), and CD138 + IL-10 + TGFβ + Bregs (yellow) within TLSs. (F) Cumulative data showing the frequencies of CD138 + IL-10 + Bregs, CD20 + CD138 + TGFβ + Bregs, CD138 + IL-10 + TGFβ + Bregs within ROIs; * p <0.05, ** p <0.01. 13 ROIs across n =3 biologically independent samples. One-way ANOVA with Tukey’s test for multiple comparisons. Error bars represented as mean±SEM. (G) Cumulative data showing the frequencies of CD20 + CD27 - IgD + (naive), CD20 + CD27 + IgD + (unswitched memory (USM)), CD20 + CD27 + IgD - B cells, CD20 + CD27 - IgD - CD21 + CD11c - (DN1), CD20 + CD27 - IgD - CD21 - CD11c + (DN2), CD20 + CD27 - IgD - CD21 - CD11c - (DN3), and CD20 + CD27 - IgD - CD21 + CD11c + (DN4) within CD20 + IL-10 + Bregs; * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001. 13 ROIs across n =3 biologically independent samples. Fridman test with Dunn’s test for multiple comparisons. Error bars represented as mean±SEM. (H) Cumulative data showing the frequencies of CD20 + CD27 - IgD + (naive), CD20 + CD27 + IgD + (unswitched memory (USM)), CD20 + CD27 - IgD - (double negative (DN)), CD20 + CD27 + IgD - B cells, CD20 + CD27 - IgD - CD21 + CD11c - (DN1), CD20 + CD27 - IgD - CD21 - CD11c + (DN2), CD20 + CD27 - IgD - CD21 - CD11c - (DN3), and CD20 + CD27 - IgD - CD21 + CD11c + (DN4) B cells within CD20 + TGFβ + Bregs; * p <0.05, ** p <0.01. 13 ROIs across n =3 biologically independent samples. Fridman test with Dunn’s test for multiple comparisons. Error bars represented as mean±SEM. (I) Prognostic association of high versus low CD19, IL-10, TGFB1 signature with survival in RCC using The Cancer Genome Atlas (TCGA) data. p values were derived by Cox proportional hazard model adjusting for signature group, age, sex, and American Joint Committee on Cancer (AJCC) stage.
Article Snippet: Tissue-resident B cells were isolated using the EasySep immunomagnetic CD19 positive selection kit (STEMCELL, cat. no. 17854).
Techniques: Expressing, Staining, Derivative Assay